Six-Amino Acid Peptide Blocking CD40-CD154 in Multiple Sclerosis

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for autoimmune diseases like multiple sclerosis (MS) face challenges due to severe side effects and complications from using monoclonal antibodies and other immunosuppressants, and there is a need for safer and more effective methods to inhibit the CD40-CD154 interaction, which is critical in autoimmune inflammation.

Innovation Solution

The use of specific peptides, particularly a 6-amino acid sequence (KGYY6), designed to interact with the CD40 protein and inhibit its interaction with CD154, thereby modulating T-cell activity and reducing autoimmune inflammation.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If monoclonal antibodies are used to treat multiple sclerosis, then immune suppression is achieved, but severe side effects and complications occur

Engineering Contradiction:

Improvetreatment effectivenessVSAvoidside effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent extracts only the essential functional portion of the antibody (the antigen-binding fragment) to create a peptide that retains the ability to inhibit CD40-CD154 interaction while removing the problematic full antibody structure that causes severe side effects

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The invention uses a short peptide sequence instead of a full monoclonal antibody, creating a smaller, simpler molecule that achieves the therapeutic effect without the complications associated with larger antibody molecules

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

2Reliability

If larger molecules like monoclonal antibodies are used, then immune modulation is achieved, but complications arise

Engineering Contradiction:

Improveimmune modulation efficacyVSAvoidmolecule size

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent extracts the critical antigen-binding region from the full antibody molecule, creating a minimized peptide sequence that maintains immunomodulatory function while dramatically reducing molecular complexity and size

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The invention creates a simplified copy or mimic of the antibody's essential functional element (the antigen-binding fragment), which replicates the therapeutic effect without requiring the complete antibody structure

Inventive Principle:

Principle #26Copying

Data Source

PatentUS12472223B2Methods for reducing symptoms of multiple sclerosis using a six-amino acid long peptide that inhibits CD40-CD154 interaction

Publication Date: 2025.11.18 OP T LLC

AI summary

Methods and materials for treating and preventing autoimmune diseases, in particular, multiple sclerosis (MS) including small peptides are capable of interacting with CD40, thereby altering and/or modulating the ability of CD40 to interact with CD154, which apparently affects inflammation; and/or the use of such peptides in reducing the inflammatory response, and in particular, the autoimmune inflammatory response; and/or the use of such short peptides to prevent or reverse autoimmune disease, and particularly, multiple sclerosis, in individuals; and/or methods and materials for detecting T-cells that express CD40 (Th40 cells). Also provided are kits for reducing inflammation, treating autoimmune diseases, or detecting Th40 cells. Additionally, methods and apparatuses to administer the peptide are provided.